Hindustan Bio Sciences posts ₹11.29 lakh loss in Q1FY27 on zero revenue
Hindustan Bio Sciences Limited posted a standalone net loss of ₹11.29 lakh for Q1FY27, reversing the ₹1.40 lakh profit from Q1FY26. The loss stems from zero operational revenue against persistent fixed expenses of ₹11.29 lakh, primarily employee benefits. The Board approved the results on July 31, 2026, and scheduled the 34th AGM for September 30, 2026.
*this image is generated using AI for illustrative purposes only.
Hindustan Bio Sciences Limited reported a standalone net loss of ₹11.29 lakh for the first quarter ended June 30, 2026 (Q1FY27), widening from the net profit of ₹1.40 lakh recorded in Q1FY26. The deterioration was driven by zero revenue from operations, compared to ₹32.19 lakh in the corresponding period of FY26, signaling a complete cessation of trading activities. Despite the absence of operational income, the company incurred total expenses of ₹11.29 lakh, primarily comprising employee benefit expenses of ₹5.72 lakh and other expenses of ₹5.56 lakh. This divergence between nil revenue and sustained fixed costs poses ongoing liquidity risks for shareholders.
The Board of Directors approved the unaudited standalone financial results on July 31, 2026, in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Vasg & Associates, who issued an unmodified opinion. The company operates in a single reportable segment: Trading of Pharmaceuticals.
Financial Performance
The financial data reveals a sharp contraction in top-line activity while fixed costs persisted. In Q1FY27, revenue from operations was nil, and other income was also zero. This contrasts with Q1FY26, where the company generated ₹32.19 lakh from operations and ₹1.31 lakh from other income.
| Particulars | Q1FY27 (₹ in Lakhs) | Q1FY26 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 0.00 | 32.19 |
| Other Income | 0.00 | 1.31 |
| Total Revenue | 0.00 | 33.50 |
| Total Expenses | 11.29 | 32.11 |
| Net Profit/(Loss) | (11.29) | 1.40 |
Employee benefit expenses increased slightly to ₹5.72 lakh from ₹4.40 lakh in the previous year’s quarter. Purchases of stock-in-trade, which accounted for ₹21.19 lakh in Q1FY26, dropped to zero in the current quarter, aligning with the absence of operational revenue. Finance costs and selling expenses were negligible, recorded at ₹0.00 lakh and ₹0.01 lakh respectively.
What the Numbers Show
The most critical observation is the complete cessation of revenue generation alongside persistent operational expenditures. While the company avoided variable costs such as purchases of stock-in-trade and material consumption, it continued to incur fixed overheads, particularly employee benefits and other administrative expenses. This divergence between zero revenue and sustained expenses directly caused the swing from a profit position in Q1FY26 to a loss in Q1FY27. The lack of any other income further exacerbated the bottom-line pressure, indicating no offsetting gains from investments or interest during the period.
Corporate Governance Updates
In addition to approving the financial results, the Board fixed the date for the 34th Annual General Meeting (AGM) as Wednesday, September 30, 2026, at 10:00 A.M. The meeting will be held at the company’s registered office in Hyderabad. Mr. VBSS Prasad, a practicing Company Secretary, was appointed as the scrutinizer to oversee the remote e-voting process and voting at the venue, ensuring transparency in shareholder participation. The notice convening the AGM, along with the Directors’ Report and Corporate Governance Report for FY26, was also approved.
Historical Stock Returns for Hindustan Bio Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.00% | -0.15% | -3.52% | -13.60% | -16.65% | +113.04% |
What specific strategic initiatives is Hindustan Bio Sciences pursuing to restart pharmaceutical trading activities and generate revenue in Q2FY27?
How does the company plan to manage its liquidity position given the continued burn rate of fixed expenses without any operational cash inflow?
Are there any pending regulatory approvals or supply chain disruptions that contributed to the complete cessation of trading, and when might these be resolved?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
